<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>
      Lifestyle | China Emerges as Powerhouse in Next-Gen Obesity Drugs
    </title>
    <link rel="stylesheet" href="/tnj-chronicles.css" />
    <script src="/main.js" defer></script>
    <link rel="icon" type="image/png" href="/assets/images/logos/icon.webp" />
  </head>
  <body>
    <main class="blog-container">
      <header>
        <nav>
          <ul>
            <li><a href="/" target="_blank">TNJ Media</a></li>
            <li><a href="/Catalogue">Catalogue</a></li>
            <li><a href="/About_TNJ-Chronicles">About</a></li>
          </ul>
          <div>
            <a href="/TNJ-Chronicles" class="tnj-chronicles-logo">
              <img
                src="/assets/images/logos/tnjchronicles-logo.webp"
                alt="TNJ-Chronicles"
                id="tnj-chronicles-logo"
                class="active"
              />
            </a>
          </div>
          <p>
            Follow Us &nbsp;
            <a href="https://www.instagram.com/tnjmediasa/" target="_blank">
              @tnjmediasa
            </a>
          </p>
        </nav>
        <h1 class="menu-toggle" id="menuToggle">☰</h1>
        <div class="mobile-menu" id="mobileMenu">
          <ul>
            <li><a href="/" target="_blank">TNJ Media</a></li>
            <li><a href="/TNJ-Chronicles">TNJ Chronicles</a></li>
            <li><a href="/Catalogue">Catalogue</a></li>
            <li><a href="/About_TNJ-Chronicles">About</a></li>
          </ul>
          <p>
            Follow Us &nbsp;
            <a href="https://www.instagram.com/tnjmediasa/" target="_blank">
              @tnjmediasa
            </a>
          </p>
        </div>
      </header>

      <div class="heading">
        <h1>
          Lifestyle
          <em>China Emerges as Powerhouse in Next-Gen Obesity Drugs</em>
        </h1>
        <p class="date">June 30, 2025 ● Tebuho Zongwana</p>
      </div>

      <div class="content">
        <div class="side-bar">
          <div class="side-bar-content">
            <div class="popular-blog">
              <h2>Popular Blogs:</h2>
              <a href="/blog-pages/FightingFungus">
                <h2>Lifestyle</h2>
                <p>Fighting Fungus on a `High`</p>
              </a>
              <a href="/blog-pages/ChineseRockete_Commerce">
                <h2>Tech News</h2>
                <p>
                  Chinese rocket delivers e-Commerce packages in sea recovery
                  test
                </p>
              </a>
            </div>
          </div>
        </div>

        <article>
          <img
            src="/blog-pages/imges/news/ChinaObesity.webp"
            alt="China Obesity Drug Innovation"
          />
          <h2>China Emerges as Powerhouse in Next-Gen Obesity Drugs</h2>
          <p>
            Chinese pharmaceutical companies are transitioning from producing
            copies of global blockbusters like Wegovy and Ozempic to developing
            innovative obesity treatments of their own.
          </p>
          <p>
            A notable breakthrough is ecnoglutide, a GLP 1 receptor agonist like
            semaglutide but with distinct biochemical properties. In a phase 3
            trial involving 664 participants, those who received a weekly 2.4 mg
            dose lost an average of 13.8 kg over 48 weeks. In contrast, the
            placebo group lost just 0.2 kg. Nearly 93% of individuals on
            ecnoglutide lost at least 5% of their body weight, compared to 14%
            in the placebo group. Importantly, weight regain was minimal—around
            1% in the seven weeks following treatment. The drug also improved
            cardiovascular health, reduced liver fat, and boosted blood-sugar
            control.
          </p>
          <p>
            China is currently testing dozens of similar therapies. Another
            promising candidate is mazdutide, which targets both GLP 1 and
            glucagon receptors. Developed by Eli Lilly and produced in Suzhou
            under license by Innovent, it resulted in about 15% weight loss over
            36 weeks, with additional heart health benefits.
          </p>
          <p>
            Experts suggest this new generation of drugs will lead to more
            personalized treatments for obesity-related conditions such as fatty
            liver disease, sleep apnea, chronic kidney disease, and heart
            disease—making advanced care more accessible and effective.
          </p>
          <div class="side-bar" id="side-bar">
            <div class="side-bar-content">
              <div class="popular-blog">
                <h2>Popular Blogs:</h2>
                <a href="/blog-pages/FightingFungus">
                  <h2>Lifestyle</h2>
                  <p>Fighting Fungus on a `High`</p>
                </a>
                <a href="/blog-pages/ChineseRockete_Commerce">
                  <h2>Tech News</h2>
                  <p>
                    Chinese rocket delivers e-Commerce packages in sea recovery
                    test
                  </p>
                </a>
              </div>
            </div>
          </div>
        </article>

        <div class="share">
          <p>Share:</p>
          <a href="https://www.facebook.com" target="_blank">
            <img src="/assets/images/icons/facebook.webp" alt="Facebook" />
          </a>
          <a href="https://www.twitter.com" target="_blank">
            <img src="/assets/images/icons/twitter.webp" alt="Twitter" />
          </a>
          <a href="https://www.instagram.com" target="_blank">
            <img src="/assets/images/icons/instagram.webp" alt="Instagram" />
          </a>
        </div>
      </div>
    </main>

    <script src="/script.js"></script>
  </body>
</html>
